AJP - Endo Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 289: E258-E265, 2005. First published March 22, 2005; doi:10.1152/ajpendo.00311.2004
0193-1849/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/2/E258    most recent
00311.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aftab Guy, D.
Right arrow Articles by Davis, S. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aftab Guy, D.
Right arrow Articles by Davis, S. N.

Effects of glycemic control on target organ responses to epinephrine in type 1 diabetes

Deanna Aftab Guy,2 Darleen Sandoval,1 M. A. Richardson,1 Donna Tate,1 and Stephen N. Davis1,3

1Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, and 2Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Vanderbilt University School of Medicine; and 3Nashville Veterans Affairs Medical Center, Nashville, Tennessee

Submitted 14 July 2004 ; accepted in final form 15 March 2005

Severe hypoglycemia occurs in intensively treated patients with type 1 diabetes mellitus (T1DM) due in part to deficient epinephrine counterregulatory responses. Previously, we have found that T1DM patients demonstrated a spectrum of altered responses to epinephrine at a variety of target organs compared with nondiabetic healthy subjects. What is not known is whether intensive glycemic control further modifies target organ responses in individuals with T1DM. Therefore, the aim of this study is to assess whether there is tissue specific (liver, muscle, adipose tissue, pancreas and cardiovascular) resistance to epinephrine in intensively controlled (IC) T1DM compared with those with conventional control (CC). Eight IC patients (age 33 ± 4 yr, BMI 24 ± 2 kg/m2, Hb A1C 6.7 ± 0.1%), and 11 CC patients (age 35 ± 3 yr, BMI 25 ± 1 kg/m2, Hb A1C 9.6 ± 0.1%) underwent two separate randomized, single-blind, 2-h hyperinsulinemic euglycemic clamp studies with (EPI) and without (NO EPI) epinephrine infusion. Epinephrine levels during EPI were similar in all groups (5,197 ± 344 pmol/l). Glucose (5.3 ± 0.1 mmol/l) and insulin levels (515 ± 44 pmol/l) were similar in all groups during the glucose clamps. Endogenous glucose production (EGP) and glucose uptake (Rd) were determined using [3-H3]glucose. Muscle biopsy was performed at the end of each study. IC had a significantly reduced EGP and Rd responses to EPI compared with CC. Glucagon responses to EPI were similarly blunted in both IC and CC. Free fatty acid and glycerol response to EPI was greater in CC compared with IC. There was a significantly greater systolic blood pressure response to EPI in CC. We conclude that, despite similar epinephrine, insulin, and glucose levels, intensively treated T1DM patients had reduced cardiovascular, skeletal muscle, hepatic, and adipose target organ responses to EPI compared with conventionally treated T1DM patients.

catecholamines; metabolic target organ; intensive glucose control; glucose clamp technique



Address for reprint requests and other correspondence: S. N. Davis, 715 PRB, Div. of Diabetes, Endocrinology & Metabolism, Vanderbilt Univ. School of Medicine, Nashville, TN 37232-6303




This article has been cited by other articles:


Home page
DiabetesHome page
V. J. Briscoe, A. C. Ertl, D. B. Tate, S. Dawling, and S. N. Davis
Effects of a Selective Serotonin Reuptake Inhibitor, Fluoxetine, on Counterregulatory Responses to Hypoglycemia in Healthy Individuals
Diabetes, September 1, 2008; 57(9): 2453 - 2460.
[Abstract] [Full Text] [PDF]


Home page
Clin. DiabetesHome page
V. J. Briscoe and S. N. Davis
Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management
Clin. Diabetes, July 1, 2006; 24(3): 115 - 121.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.